Climb Bio (CLYM) Income from Continuing Operations (2020 - 2026)
Climb Bio (CLYM) posted Income from Continuing Operations of 46053000.0 for Q1 2026, down 57.73% on a QoQ basis from 29197000.0 in Q4 2025, and down 116.57% year-over-year from 277978156.4 in Q1 2025.
Climb Bio (CLYM) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Climb Bio's Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 46053000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 116.57% year-over-year to 46053000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98251000.0 (down 0.81% YoY) and the FY2025 annual result came in at 71287000.0, up 30.37% from the prior year.
- Income from Continuing Operations was 46053000.0 for Q1 2026 at Climb Bio, down from 29197000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2737000.0 in Q1 2024 and bottomed at 57675000.0 in Q2 2024.
- A 5-year average of 20338176.47 and a median of 17491000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations surged 89.04% — and 2025, when it tumbled 676.95%.
- Climb Bio's Income from Continuing Operations stood at 25553000.0 in 2022, then advanced by 3.62% to 24629000.0 in 2023, then soared by 64.92% to 8640000.0 in 2024, then slumped by 237.93% to 29197000.0 in 2025, then slumped by 57.73% to 46053000.0 in 2026.
- Business Quant data shows CLYM's Income from Continuing Operations at 46053000.0 in Q1 2026, 29197000.0 in Q4 2025, and 14461000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Climb Bio | 870.33 Mn | 870.33 Mn | - | -46.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.05 Mn |
| Dec 31, 2025 | -29.20 Mn |
| Sep 30, 2025 | -14.46 Mn |
| Jun 30, 2025 | -8.54 Mn |
| Mar 31, 2025 | -21.27 Mn |
| Dec 31, 2024 | -8.64 Mn |
| Sep 30, 2024 | -9.88 Mn |
| Jun 30, 2024 | -57.68 Mn |
| Mar 31, 2024 | -2.74 Mn |
| Dec 31, 2023 | -24.63 Mn |
| Sep 30, 2023 | -5.06 Mn |
| Jun 30, 2023 | -7.84 Mn |
| Mar 31, 2023 | -24.98 Mn |
| Dec 31, 2022 | -25.55 Mn |
| Sep 30, 2022 | -12.65 Mn |
| Jun 30, 2022 | -17.49 Mn |
| Mar 31, 2022 | -29.11 Mn |
| Dec 31, 2021 | -31.85 Mn |
| Sep 30, 2021 | -51.11 Mn |
| Jun 30, 2021 | -32.19 Mn |